Total Payments
$3.0M
2024 Payments
$525,653
Companies
22
Transactions
3,496
Medicare Patients
903
Medicare Billing
$65,065
Payment Breakdown by Category
Other$2.4M (79.6%)
Travel$379,351 (12.8%)
Consulting$135,200 (4.6%)
Food & Beverage$77,284 (2.6%)
Research$12,021 (0.4%)
Education$254.31 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.4M | 879 | 79.6% |
| Travel and Lodging | $379,351 | 1,333 | 12.8% |
| Consulting Fee | $135,200 | 55 | 4.6% |
| Food and Beverage | $77,284 | 1,216 | 2.6% |
| Unspecified | $12,021 | 5 | 0.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,330 | 1 | 0.0% |
| Education | $254.31 | 7 | 0.0% |
Payments by Type
General
$3.0M
3,491 transactions
Research
$12,021
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1.1M | 1,435 | $0 (2024) |
| GlaxoSmithKline, LLC. | $522,391 | 580 | $0 (2024) |
| GENZYME CORPORATION | $465,277 | 368 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $307,895 | 306 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $240,427 | 248 | $0 (2023) |
| PFIZER INC. | $95,066 | 171 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $82,126 | 147 | $0 (2020) |
| Amgen Inc. | $38,823 | 58 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $36,874 | 50 | $0 (2019) |
| Genentech USA, Inc. | $36,000 | 45 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $525,653 | 428 | GENZYME CORPORATION ($170,172) |
| 2023 | $488,605 | 551 | AstraZeneca Pharmaceuticals LP ($146,009) |
| 2022 | $519,796 | 574 | AstraZeneca Pharmaceuticals LP ($173,794) |
| 2021 | $335,075 | 352 | AstraZeneca Pharmaceuticals LP ($142,843) |
| 2020 | $85,833 | 103 | GlaxoSmithKline, LLC. ($47,337) |
| 2019 | $361,192 | 500 | AstraZeneca Pharmaceuticals LP ($140,136) |
| 2018 | $339,993 | 505 | AstraZeneca Pharmaceuticals LP ($166,064) |
| 2017 | $306,762 | 483 | AstraZeneca Pharmaceuticals LP ($153,915) |
All Payment Transactions
3,496 individual payment records from CMS Open Payments — Page 1 of 140
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $150.00 | General |
| Category: Respiratory | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,438.00 | General |
| 12/17/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $11.84 | General |
| Category: HFCWO | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $332.16 | General |
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $36.84 | General |
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,438.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $700.64 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $604.63 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $159.85 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $126.42 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $45.92 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | Cash or cash equivalent | $15.06 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,088.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,098.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Travel and Lodging | In-kind items and services | $1,108.37 | General |
| Category: Immunology | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $112.95 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $90.04 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,438.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,758.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Travel and Lodging | In-kind items and services | $1,730.82 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,728.84 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Travel and Lodging | In-kind items and services | $975.83 | General |
| Category: Immunology | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Travel and Lodging | In-kind items and services | $301.86 | General |
| Category: Immunology | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $138.98 | General |
| Category: Immunology | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | Cash or cash equivalent | $50.80 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, 7 MONTH, RANDOMIZED, DOUBLE BLIND PARALLEL GROUP, PLACEBO CONTROLLED, MULTI-CENTER TRIAL WITH A 5 MONTH EXTENSION PERIOD TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, STEROID REDUCTION, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS RHUMAB-E25 IN ADOLOESCENTS AND ADULTS REQUIRING DAILY TREATMENT WITH INHALED CORTICOSTEROIDS US, A PHASE 3, 7 MONTH, RANDOMIZED, DOUBLE BLIND PARALLEL GROUP, PLACEBO CONTROLLED, MULTI-CENTER TRIAL WITH A 5 MONTH EXTENSION PERIOD TO ASSESS THE EFF | F. Hoffmann-La Roche AG | $4,521 | 1 |
| A phase 3, 7 month, randomized, double blind parallel group, placebo controlled, multi-center trial with a 5 month extension period to assess the efficacy, safety, tolerability, steroid reduction, pharmacokinetics, and pharmacodynamics of subcutaneous rhuMAB-E25 in adoloescents and adults requiring daily treatment with inhaled corticosteroids US, A phase 3, 7 month, randomized, double blind parallel group, placebo controlled, multi-center trial with a 5 month extension period to assess the | F. Hoffmann-La Roche AG | $3,499 | 2 |
| AGE OF ASTHMA ONSET DOES NOT IMPACT THE RESPONSE TO OMALIZUMAB | F. Hoffmann-La Roche AG | $2,076 | 1 |
| A phase 3, 7 month, randomized, double blind parallel group, placebo controlled, multi-center trial with a 5 month extension period to assess the efficacy, safety, tolerability, steroid reduction, pharmacokinetics, and pharmacodynamics of subcutaneous rhuMAB-E25 in adoloescents and adults requiring daily treatment with inhaled corticosteroids (US) | F. Hoffmann-La Roche AG | $1,925 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 76 | 92 | $57,191 | $8,353 |
| 2022 | 3 | 102 | 152 | $63,604 | $9,683 |
| 2021 | 4 | 116 | 225 | $97,165 | $18,172 |
| 2020 | 12 | 609 | 775 | $157,032 | $28,857 |
Total Patients
903
Total Services
1,244
Medicare Billing
$65,065
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 35 | 47 | $23,594 | $3,127 | 13.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 31 | $21,669 | $3,122 | 14.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $11,928 | $2,104 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 77 | $37,406 | $5,420 | 14.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 27 | 33 | $22,387 | $3,961 | 17.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 25 | 42 | $3,811 | $302.41 | 7.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 52 | 130 | $54,865 | $9,872 | 18.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 33 | 58 | $35,195 | $7,099 | 20.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 19 | $5,341 | $982.19 | 18.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 15 | 18 | $1,764 | $218.88 | 12.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 95 | 196 | $69,324 | $11,564 | 16.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 52 | 80 | $37,505 | $6,331 | 16.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 53 | $17,172 | $4,630 | 27.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $6,919 | $1,795 | 25.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 13 | $2,925 | $800.45 | 27.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 19 | 20 | $4,667 | $697.33 | 14.9% |
| 94375 | Diagnostic testing in a pulmonary function lab | Office | 2020 | 66 | 67 | $3,685 | $610.04 | 16.6% |
| 94726 | Determination of lung volumes using plethysmography | Office | 2020 | 76 | 78 | $3,588 | $562.10 | 15.7% |
| 94729 | Measurement of lung diffusing capacity | Office | 2020 | 87 | 89 | $3,026 | $503.50 | 16.6% |
| 94618 | Test for exercise-induced lung stress | Facility | 2020 | 17 | 17 | $1,428 | $271.14 | 19.0% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2020 | 37 | 37 | $1,702 | $268.36 | 15.8% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2020 | 38 | 38 | $1,292 | $205.44 | 15.9% |
| 94375 | Diagnostic testing in a pulmonary function lab | Facility | 2020 | 25 | 25 | $1,375 | $204.71 | 14.9% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2020 | 24 | 24 | $1,152 | $176.90 | 15.4% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2020 | 15 | 15 | $720.00 | $131.95 | 18.3% |
About Dr. Samuel Louie, M.D
Dr. Samuel Louie, M.D is a Internal Medicine healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1811972920.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samuel Louie, M.D has received a total of $3.0M in payments from pharmaceutical and medical device companies, with $525,653 received in 2024. These payments were reported across 3,496 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.4M).
As a Medicare-enrolled provider, Louie has provided services to 903 Medicare beneficiaries, totaling 1,244 services with total Medicare billing of $65,065. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Sacramento, CA
- Active Since 12/12/2005
- Last Updated 10/25/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1811972920
Products in Payments
- DUPIXENT (Biological) $578,644
- BREZTRI (Drug) $262,414
- FASENRA (Drug) $240,196
- TEZSPIRE (Biological) $182,997
- BEVESPI AEROSPHERE (Drug) $182,321
- FASENRA (Biological) $169,534
- TRELEGY ELLIPTA (Drug) $165,329
- NUCALA (Biological) $149,606
- ELIQUIS (Drug) $115,028
- AREXVY (Drug) $104,819
- LONHALA MAGNAIR (Drug) $64,628
- Xolair (Biological) $47,798
- AIRSUPRA (Drug) $43,938
- SYMBICORT (Drug) $31,581
- SPIRIVA (Drug) $28,835
- STIOLTO RESPIMAT (Drug) $21,246
- BREZTRI AEROSPHERE (Drug) $16,988
- CHANTIX (Drug) $16,912
- ANORO (Drug) $15,358
- UTIBRON (Drug) $11,868
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Sacramento
Dr. Christian Sandrock, Md, MD
Internal Medicine — Payments: $2.3M
Internal Medicine $2.3M
Thomas Smith, M.d, M.D
Internal Medicine — Payments: $1.0M
Internal Medicine $1.0M
Arash Aryana, M.d, M.D
Internal Medicine — Payments: $588,584
Internal Medicine $588,584
Dr. Jonathan Riess, M.d., M.s, M.D., M.S
Internal Medicine — Payments: $191,089
Internal Medicine $191,089
Dr. Ken Yoneda, Md, MD
Internal Medicine — Payments: $183,967
Internal Medicine $183,967
George Thompson Iii, Md, MD
Internal Medicine — Payments: $164,133
Internal Medicine $164,133